Literature DB >> 20721648

Bazex syndrome (acrokeratosis paraneoplastica) diagnosed in a patient with oral persistent ulcerations.

Alan Roger Santos-Silva1, Marcelo Brum Correa, Pablo Agustin Vargas, Oslei Paes Almeida, Marcio Ajudarte Lopes.   

Abstract

Paraneoplastic syndromes associated with head and neck cancer are rare and have been reported under dermatological, endocrine, hematological, neurological and rheumatological disorders. Bazex syndrome is an intriguing paraneoplasia that can be associated with head and neck squamous cell carcinomas. A range of symmetrical dermatological manifestations, with a clear predilection to extremities, that encompasses erythematous squamous plaques, skin scaling and nail dystrophy can provide a psoriasiform pattern in Bazex syndrome. In addition to these tricky clinical features, the rarity of the disease and the lack of understanding on Bazex syndrome generally make such cases to be mismanaged as psoriasis or lichen planus, causing an important delay in the diagnosis of the underlying malignancy. The authors describe a case of Bazex syndrome that occurred in a patient with a recently diagnosed tongue squamous cell carcinoma. Clinicians should consider paraneoplasia when assessing skin and/or oral persistent lesions.

Entities:  

Mesh:

Year:  2010        PMID: 20721648      PMCID: PMC2996492          DOI: 10.1007/s12105-010-0203-5

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  11 in total

1.  Bullous lesions in Bazex syndrome and successful treatment with oral psoralen phototherapy.

Authors:  D Gill; P Fergin; J Kelly
Journal:  Australas J Dermatol       Date:  2001-11       Impact factor: 2.875

2.  Bazex syndrome mimicking a primary autoimmune bullous disorder.

Authors:  D F Mutasim; G Meiri
Journal:  J Am Acad Dermatol       Date:  1999-05       Impact factor: 11.527

3.  Acrokeratosis paraneoplastica associated with recurrent metastatic thymic carcinoma.

Authors:  T A Chave; W M Bamford; K E Harman
Journal:  Clin Exp Dermatol       Date:  2004-07       Impact factor: 3.470

4.  Bazex syndrome (acrokeratosis paraneoplastica).

Authors:  Brian Poligone; Sean R Christensen; Rossitza Lazova; Peter W Heald
Journal:  Lancet       Date:  2007-02-10       Impact factor: 79.321

Review 5.  Bazex syndrome (acrokeratosis paraneoplastica).

Authors:  B Sarkar; R Knecht; C Sarkar; H Weidauer
Journal:  Eur Arch Otorhinolaryngol       Date:  1998       Impact factor: 2.503

Review 6.  Bazex syndrome (acrokeratosis paraneoplastica). An analytic review.

Authors:  J L Bolognia; Y P Brewer; D L Cooper
Journal:  Medicine (Baltimore)       Date:  1991-07       Impact factor: 1.889

7.  Acrokeratosis paraneoplastica (Bazex syndrome) occurring with acquired ichthyosis in Hodgkin's disease.

Authors:  G P Lucker; P M Steijlen
Journal:  Br J Dermatol       Date:  1995-08       Impact factor: 9.302

8.  Acrokeratosis paraneoplastica (Bazex' syndrome).

Authors:  F K Jacobsen; N Abildtrup; S O Laursen; F Brandrup; N K Jensen
Journal:  Arch Dermatol       Date:  1984-04

Review 9.  Epidermal manifestations of internal malignancy.

Authors:  Rachael L Moore; Theresa S Devere
Journal:  Dermatol Clin       Date:  2008-01       Impact factor: 3.478

Review 10.  Acrokeratosis paraneoplastica (Bazex' syndrome). Report of a case and review of the literature.

Authors:  A L Pecora; L Landsman; S P Imgrund; W C Lambert
Journal:  Arch Dermatol       Date:  1983-10
View more
  3 in total

1.  [Paraneoplastic palmoplantar hyperkeratosis. Minor form of acrokeratosis neoplastica Bazex?].

Authors:  L M Ehmann; M Grahovac; M Kramer; T Ruzicka; A Wollenberg
Journal:  Hautarzt       Date:  2012-06       Impact factor: 0.751

Review 2.  A Review of Nail Changes in Acrokeratosis Paraneoplastica (Bazex Syndrome).

Authors:  Bipasha Roy; Shari R Lipner
Journal:  Skin Appendage Disord       Date:  2021-03-02

3.  An Unconventional Presentation of Multiple Myeloma: Bazex Syndrome

Authors:  Özlem Kandemir Alibakan; Naciye Demirel; Nihan Nizam; Rafet Eren
Journal:  Turk J Haematol       Date:  2020-08-24       Impact factor: 1.831

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.